The weight-loss drug Wegovy slashes the risk of heart disease even before people shed many pounds, data suggests.The drug, which contains the active ingredient semaglutide, works by reducing food ...

The diabetes and weight loss drugs are “not cost-effective at their current prices, and are largely unavailable to people with lower incomes,” the report said.

As medications become increasingly popular to support weight loss, not all of them are approved by the U.S. Food and Drug ...

While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Kontra Investments. In this article, we will summarize the bulls’ thesis on NVO.

The weight loss drug Wegovy treated a serious form of liver disease in about two-thirds of patients in a major clinical trial. The Fox Medical Team's Dr. Mike Cirigliano joined Good Day to take a look ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

The best metric is not weight, but a particularly toxic kind of fat.

New data suggests the weight-loss drug Wegovy may significantly reduce the risk of heart disease even before users experience ...

For the first time, scientists have pitted the two most popular weight loss drugs against each other in a direct competition ...

The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...